
Nektar Therapeutics Investor Relations Material
Latest events

Q1 2025
Nektar Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nektar Therapeutics
Access all reports
Nektar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of novel therapies. These therapies aim to selectively modulate the immune system to treat autoimmune disorders, chronic inflammatory conditions, and cancer.The company uses proprietary PEGylation and advanced polymer conjugate technologies to modify the chemical structure of substances, facilitating the development of new drug candidates. It is headquartered in San Francisco, California, and its shares are listed on the NASDAQ under the ticker symbol NKTR.
Key slides for Nektar Therapeutics


Study Update
Nektar Therapeutics


Study Update
Nektar Therapeutics
Latest articles
)
Upcoming IPOs to Watch in 2025
Potential IPOs in 2025 include prominent names like Shein, Databricks, Klarna, eToro, and Figma, to name a few. Let's take a closer look.
23 May 2025
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
Ticker symbol
NKTR
Country
🇺🇸 United States